Search research articles
Contact Us
Filters
Showing results (221-230 of 263) with videos related to
Page
of 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 14, 2023
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy
Anil P Bidkar, Sinan Wang, Kondapa Naidu Bobba, et al.
Frontiers in Oncology
|
March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer
Divya Natesan, Li Zhang, Henry J Martell, et al.
Nature Ecology & Evolution
|
June 18, 2021
Ecological factors influence balancing selection on leaf chemical profiles of a wildflower
Lauren N Carley, Julius P Mojica, Baosheng Wang, et al.
The New England Journal of Medicine
|
August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M Hyman, Igor Puzanov, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2015
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
Marc Peeters, Kelly S Oliner, Timothy J Price, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 23, 2003
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
Dirk B Mendel, A Douglas Laird, Xiaohua Xin, et al.
Clinical Colorectal Cancer
|
February 12, 2014
Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147
Jocelin Huang, Suresh G Nair, Michelle R Mahoney, et al.
The Oncologist
|
June 22, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains
Xiaolin Zhu, Emily Chan, Michelle L Turski, et al.
Clinical Genitourinary Cancer
|
June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin
Tanya Jindal, Li Zhang, Prianka Deshmukh, et al.
Analytical Chemistry
|
March 6, 2023
Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry
John C Tran, Thomas Hunsaker, Christina Bell, et al.
Page
of 27
Search research articles
Search
Showing results (221-230 of 263) with videos related to
Sort By:
Page
of 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 14, 2023
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy
Anil P Bidkar, Sinan Wang, Kondapa Naidu Bobba, et al.
Frontiers in Oncology
|
March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer
Divya Natesan, Li Zhang, Henry J Martell, et al.
Nature Ecology & Evolution
|
June 18, 2021
Ecological factors influence balancing selection on leaf chemical profiles of a wildflower
Lauren N Carley, Julius P Mojica, Baosheng Wang, et al.
The New England Journal of Medicine
|
August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M Hyman, Igor Puzanov, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2015
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
Marc Peeters, Kelly S Oliner, Timothy J Price, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 23, 2003
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
Dirk B Mendel, A Douglas Laird, Xiaohua Xin, et al.
Clinical Colorectal Cancer
|
February 12, 2014
Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147
Jocelin Huang, Suresh G Nair, Michelle R Mahoney, et al.
The Oncologist
|
June 22, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains
Xiaolin Zhu, Emily Chan, Michelle L Turski, et al.
Clinical Genitourinary Cancer
|
June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin
Tanya Jindal, Li Zhang, Prianka Deshmukh, et al.
Analytical Chemistry
|
March 6, 2023
Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry
John C Tran, Thomas Hunsaker, Christina Bell, et al.
Page
of 27